BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. J Intensive Care 2018;6:61. [PMID: 30221005 DOI: 10.1186/s40560-018-0330-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Neyra JA, Yessayan L, Thompson Bastin ML, Wille KM, Tolwani AJ. How To Prescribe And Troubleshoot Continuous Renal Replacement Therapy: A Case-Based Review. Kidney360 2021;2:371-84. [PMID: 35373031 DOI: 10.34067/KID.0004912020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Scharf C, Weinelt F, Schroeder I, Paal M, Weigand M, Zoller M, Irlbeck M, Kloft C, Briegel J, Liebchen U. Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study. Ann Intensive Care 2022;12:44. [PMID: 35599248 DOI: 10.1186/s13613-022-01017-5] [Reference Citation Analysis]
3 Honore PM, Redant S, Djimafo P, Preseau T, Cismas BV, Kaefer K, Barreto Gutierrez L, Anane S, Gallerani A, Attou R. Letter to the Editor : "An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy". J Crit Care 2022;70:154058. [PMID: 35561558 DOI: 10.1016/j.jcrc.2022.154058] [Reference Citation Analysis]
4 Philpott CD, Droege CA, Droege ME, Healy DP, Courter JD, Ernst NE, Harger NJ, Foertsch MJ, Winter JB, Carter KE, Van Fleet SL, Athota K, Mueller EW. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study. Pharmacotherapy 2019;39:1066-76. [PMID: 31549737 DOI: 10.1002/phar.2332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet 2022. [PMID: 35764774 DOI: 10.1007/s40262-022-01137-y] [Reference Citation Analysis]
6 Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, Liang P, Bu Y, Zhao R, Liao Y, Yang P, Lu X, Jiang S. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol 2020;11:786. [PMID: 32547394 DOI: 10.3389/fphar.2020.00786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
7 Sember AM, LoFaso ME, Lewis SJ. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy. J Crit Care 2022;69:154011. [PMID: 35202996 DOI: 10.1016/j.jcrc.2022.154011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chaijamorn W, Charoensareerat T, Rungkitwattanakul D, Phunpon S, Sathienluckana T, Srisawat N, Pattharachayakul S. Levetiracetam dosing in patients receiving continuous renal replacement therapy. Epilepsia 2021. [PMID: 34247386 DOI: 10.1111/epi.16971] [Reference Citation Analysis]
9 Al-Shaer MH, Philpott CD, Droege CA, Courter JD, Healy DP, Droege ME, Ernst NE, Mueller EW, Peloquin CA. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother 2021;65:e00144-21. [PMID: 33722885 DOI: 10.1128/AAC.00144-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chaijamorn W, Rungkitwattanakul D, Pattharachayakul S, Singhan W, Charoensareerat T, Srisawat N. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. J Crit Care 2020;60:285-9. [PMID: 32949895 DOI: 10.1016/j.jcrc.2020.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rungkitwattanakul D, Charoensareerat T, Kerdnimith P, Kosumwisaisakul N, Teeranaew P, Boonpeng A, Pattharachayakul S, Srisawat N, Chaijamorn W. Imipenem dosing recommendations for patients undergoing continuous renal replacement therapy: systematic review and Monte Carlo simulations. Ren Replace Ther 2021;7. [DOI: 10.1186/s41100-021-00380-6] [Reference Citation Analysis]
12 Rungkitwattanakul D, Chaijamorn W, Charoensareerat T, Charntrakarn P, Khamkampud O, Rattanaponpasert N, Srisawat N, Pattharachayakul S. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. J Crit Care 2021;63:154-60. [PMID: 33012583 DOI: 10.1016/j.jcrc.2020.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]